[:en]Date: 2nd November at 11.30am Venue: One Farrer Hotel, 1 Farrer Park Station Road, Singapore 217562 Dr Steven Fang will be speaking about “Strategic Investments in R/D to Accelerate Global Growth of Biotechnology Companies” detailing the following: Investment opportunities and partnerships in the Chronic disease segment Unique and advanced technologies showcase Expanding plan in Asia Co Located …
On the 1st of October, Invitrocue brought together international experts to discuss innovations in oncology and the potential of Onco-PDO as a disruptive diagnostic with KOLs. Invitrocue’s CEO Steven Fang and VP of Operations Martin Bach were joined by CEO of Invitrocue Europe Dr. Andreas Lindner, Prof Gopal Lyer from National Cancer Centre Singapore, Prof …
Assoc Prof Iyer as Chair of IVQ Medical Advisory Board
Annual Report to shareholders
Our international speakers will present the most important innovations and findings in the field of oncology. Happening on Monday, 1st October 2018, 9am – 3.45pm Venue: Klinikum rechts der Isar der Technischen Universität München Click to Download
Business updates
Invitrocue launches world’s first commercial Personalised Cancer Screening Service: Onco-PDO™
Bio-analytic healthcare provider Invitrocue (ASX: IVQ), has advanced its proprietary cancer-detection test by screening its first commercial Onco-PDO customer in Singapore.
Half Yearly Report and Accounts
Invitrocue secures grant from Northern Ireland to commercialise Onco-PDO